Indian Government To Negotiate Prices Of Imported Patented Drugs With MNCs
This article was originally published in PharmAsia News
Executive Summary
NEW DELHI - Multinational pharma companies may soon have to voluntarily price their patented drugs in India at levels that are the lowest in the world. In addition, they may have to provide a percentage waiver on the maximum retail price of the drugs that are procured in bulk for the Indian public health system
You may also be interested in...
Dual Pricing Of Patented Drugs Not Workable, Say Indian Generic Drug Makers
MUMBAI - Indian drug makers seem headed for collision with the government's moves to effect a dual pricing mechanism of patented drugs imported by multinational drug companies. Of late, the government has accelerated efforts to arrive at a consensus between Indian and multinational companies as well as non-government organizations for making patented drugs available at an affordable cost to the poorer sections of the Indian population
PharmAsia News Business Bulletin
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).